Correction to: BMC Cancer 21, 248 (2021)

https://doi.org/10.1186/s12885-021-07939-w

Following publication of the original article [1], an error was discovered in table 3 “Logistic regression model for use of antidepressants, sedatives and anti-epileptics, respectively, at one year following index date, for patients with LGG.” In this table, the numbers presented for anti-epileptics are equal to the numbers for the sedatives. There has been a copy error and numbers need to be adjusted. The new results do not change the conclusions. The updated table 3 is given below and the changed values are displayed in bold typeface.

Covariate

Univariable

Multivariable

OR (95 % CI)

p-value

OR (95 % CI)

p-value

ANTIDEPRESSANTS

 Index year (per year)

1.22 (1.07-1.39)

0.002**

1.31 (1.11-1.55)

0.002**

 Female (vs. male)

2.99 (1.60-5.60)

0.001**

3.41 (1.71-6.80)

0.001**

 Age (per year)

1.02 (1.00-1.05)

0.027*

1.02 (1.00-1.05)

0.11

 Income (per 100.000 SEK)

0.96 (0.76-1.20)

0.69

1.07 (0.83-1.39)

0.60

 Higher education (vs. lower education)

0.94 (0.78-1.15)

0.56

0.97 (0.78-1.21)

0.78

 History of depression

7.61 (3.88-14.94)

<0.001***

6.12 (2.96-12.63)

<0.001***

 Use of antidepressants preoperatively

14.15 (5.88-34.08),

<0.001***

  

 Elixhauser comorbidity index (0, 1, 2, >3)

1.33 (0.96-1.84)

0.09

1.09 (0.75-1.59)

0.65

 Functional level (per WHO performance status category)

0.98 (0.92-1.03)

0.38

0.96 (0.88-1.06)

0.42

 Tumour size (6)

1.08 (0.96-1-21)

0.22

0.92 (0.79-1.07)

0.30

SEDATIVES

 Index year (per year)

1.13 (0.99-1.29)

0.07

1.12 (0.97-1.30)

0.14

 Female (vs. male)

1.23 (0.66-2.30)

0.51

1.13 (0.58-2.19)

0.73

 Age (per year)

1.02 (1.00-1.04)

0.09

1.02 (0.99-1.04)

0.24

 Income (per 100.000 SEK)

0.87 (0.67-1.13)

0.30

0.90 (0.62-1.22)

0.49

 Higher education (vs. lower education)

0.81 (0.66-1.00)

0.05

0.90 (0.71-1.13)

0.35

 History of anxiety and/or sleeping difficulties

2.58 (1.36-4.90)

0.004**

2.14 (1.09-4.20)

0.027*

 use of sedatives preoperatively

3.05 (1.60-5.82),

<0.001***

  

 Elixhauser comorbidity index (0, 1, 2, >3)

1.37 (0.98-1.92)

0.07

1.17 (0.80-1.70)

0.41

 Functional level (per WHO performance status category)

0.97 (0.91-1.04)

0.42

0.97 (0.89-1.05)

0.43

 Tumour size (6)

1.09 (0.97-1.23)

0.17

1.00 (0.87-1.16)

0.98

ANTI-EPILEPTICS

 Index year (per year)

1.00 (0.92-1.08)

1.00

1.01 (0.92-1.12)

0.83

 Female (vs. male)

1.11 (0.75-1.64)

0.60

1.13 (0.71-1.82)

0.60

 Age (per year)

1.00 (0.98-1.01)

0.64

1.00 (0.98-1.02)

0.93

 Income (per 100.000 SEK)

1.02 (0.88-1.18)

0.79

0.94 (0.79-1.12)

0.49

 Higher education (vs. lower education)

1.04 (0.92-1.19)

0.53

1.04 (0.87-1.23)

0.69

 History of AED-use and/or seizure/epilepsy preoperatively

12.16 (7.15-20.69)

<0.001***

12.98 (7.53-22.37)

<0.001***

 Elixhauser comorbidity index (0, 1, 2, >3)

0.90 (0.69-1.17)

0.42

0.93 (0.67-1.28)

0.64

 Functional level (per WHO performance status category)

1.00 (0.99-1.01)

0.85

1.00 (0.98-1.01)

0.85

 Tumour size (6)

1.03 (0.94-1.12)

0.58

1.00 (0.90-1.13)

0.94

 Biopsy vs resection

0.78 (0.49-1.25)

0.30

0.67 (0.38 –1.19)

0.17

  1. *p <0.05, **p < 0.01, ***p < 0.001